Mainz Biomed (NASDAQ:MYNZ – Free Report) shares are set to reverse split on the morning of Tuesday, December 3rd. The 1-40 reverse split was announced on Friday, November 29th. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, December 2nd.
Mainz Biomed Trading Down 14.1 %
Shares of NASDAQ MYNZ traded down $0.04 during mid-day trading on Friday, reaching $0.22. 7,094,717 shares of the company’s stock were exchanged, compared to its average volume of 1,350,238. The business has a fifty day simple moving average of $0.26 and a 200 day simple moving average of $0.39. Mainz Biomed has a twelve month low of $0.19 and a twelve month high of $1.79.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright lowered Mainz Biomed from a “buy” rating to a “neutral” rating in a research report on Monday.
About Mainz Biomed
Mainz Biomed N.V. develops and sells in-vitro diagnostic tests for the early detection of cancer in the United States. The company offers ColoAlert, a colorectal cancer diagnostic molecular genetic stool test. It also develops PancAlert, a stool-based screening test for the detection of pancreatic cancer.
Read More
- Five stocks we like better than Mainz Biomed
- 5 discounted opportunities for dividend growth investors
- The Latest 13F Filings Are In: See Where Big Money Is Flowing
- What is a buyback in stocks? A comprehensive guide for investors
- 3 Penny Stocks Ready to Break Out in 2025
- ETF Screener: Uses and Step-by-Step Guide
- FMC, Mosaic, Nutrien: Top Agricultural Stocks With Big Potential
Receive News & Ratings for Mainz Biomed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mainz Biomed and related companies with MarketBeat.com's FREE daily email newsletter.
